secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2023-12-08T23:59:59+00:00
Accession:  0001651308-23-000170
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene renews consulting agreement with co-founder Dr. Xiaodong Wang through Dec 2026
--------------------------------------------------------------------------------

- Dr. Wang will continue as Chairman of Scientific Advisory Board under same terms as prior agreement.
- Annual fixed consulting fee remains $100,000; additional compensation possible at Company's discretion.
- Agreement effective Jan 1, 2024 to Dec 31, 2026; cancellable by Company with 30 days' notice.
- Prior consulting agreement expired Dec 31, 2023; renewal ensures continuity of scientific advisory.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000170/0001651308-23-000170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000170/bgne-20231207.htm
  HTML page:      https://secwatch.observer/filing/0001651308-23-000170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer